Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...
The Galien Foundation was established to foster and reward outstanding achievements in improving the global human condition ...
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...
at 08:35 Europe High-Altitude ... ResearchAndMarkets.com's offering.... Daiichi Sankyo (TSE:4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have been awarded The Galien Foundation 2024 Prix Galien USA ...
Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Esperion (ESPR – Research Report), retaining the price target of ...
ESPR reports a wider-than-expected loss for the third quarter of 2024. Revenues also lag estimates. Stock down in pre-market trading.
REGULATED INFORMATION Nyxoah Reports Third Quarter Financial and Operating ResultsFDA approval on track for first quarter 2025, U.S. commercial team build out in progressCompany fully funded with cash ...
Third quarter 2024 total revenue grew 42% versus prior year to $139 million, including Crysvita® revenue of $98 million and ...
Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for ...
Q2 2025 Earnings Conference Call October 31, 2024 2:30 AM ET. Company Participants. Hiroyuki Okuzawa - Representative Director, Presi ...
While the Dow Jones Industrial Average has reached all-time highs recently, one of its newest members, Merck, traded briefly Thursday morning at a 52-week low.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback